Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

Alkermes shares climbed after phase 3 LUMRYZ data met key endpoints in idiopathic hypersomnia as analysts raised price targets. Importance Rank: 1 read more

Go to News Site